Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015

Novel Agents for Relapsing Forms of Multiple Sclerosis

(2016) Rebecca Straus Farber et al.   Annual Review of Medicine

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

(2016) Steven J. Greenberg et al.   Therapeutic Advances in Neurological Disorders

Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications

(2015) Mathilde Versini et al.   BMC Medicine

Disposition of Flavonoids Impacts their Efficacy and Safety

(2015) Yong Ma et al.   CURRENT DRUG METABOLISM

ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis

(2015) Robert C. Sergott et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies

(2015) Jesus Lovera et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect

(2015) A Voldsgaard et al.   Multiple Sclerosis Journal

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect

(2015) A Voldsgaard et al.   Multiple Sclerosis Journal

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

(2014) Helena Marco et al.   BMC MUSCULOSKELETAL DISORDERS

Regulatory T cells in autoimmune neuroinflammation

(2014) Markus Kleinewietfeld et al.   IMMUNOLOGICAL REVIEWS

Therapeutic uses of anti- 4-integrin (anti-VLA-4) antibodies in multiple sclerosis

(2014) N. Schwab et al.   INTERNATIONAL IMMUNOLOGY

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

(2014) T. L. Vollmer et al.   JOURNAL OF NEUROLOGY

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

(2014) Ludwig Kappos et al.   LANCET NEUROLOGY

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

(2014) Thomas P Leist et al.   LANCET NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

 2 1 Integrin Regulates Th17 Cell Activity and Its Neutralization Decreases the Severity of Collagen-Induced Arthritis

(2013) M.-A. El Azreq et al.   JOURNAL OF IMMUNOLOGY

Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients

(2013) L. Michel et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks

(2013) Srdjan Ljubisavljevic et al.   METABOLIC BRAIN DISEASE

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial

(2013) Berit Rosche et al.   Trials

Polyunsaturated fatty acids in multiple sclerosis therapy

(2012) S. Wergeland et al.   ACTA NEUROLOGICA SCANDINAVICA

ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study)

(2012) Øivind Torkildsen et al.   ARCHIVES OF NEUROLOGY

Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer

(2012) K. D. Crew et al.   Cancer Prevention Research

Urate in Parkinson’s Disease: More Than a Biomarker?

(2012) Xiqun Chen et al.   Current Neurology and Neuroscience Reports

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival

(2012) X. Ou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Toxicity and Pathology of Selected Dietary Herbal Medicines

(2012) June K. Dunnick et al.   TOXICOLOGIC PATHOLOGY

Epigallocatechin-3-Gallate Ameliorates Experimental Autoimmune Encephalomyelitis by Altering Balance among CD4+ T-Cell Subsets

(2011) Junpeng Wang et al.   AMERICAN JOURNAL OF PATHOLOGY

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Cladribine

(2011) Thomas P. Leist et al.   CLINICAL NEUROPHARMACOLOGY

How do immune cells overcome the blood-brain barrier in multiple sclerosis?

(2011) Catherine Larochelle et al.   FEBS LETTERS

Progressive multifocal leukoencephalopathy and natalizumab

(2011) Kerstin Hellwig et al.   JOURNAL OF NEUROLOGY

Insight into the mechanism of laquinimod action

(2011) W. Brück et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

(2011) Per Soelberg Sorensen et al.   LANCET NEUROLOGY

Probiotic helminth administration in relapsing–remitting multiple sclerosis: a phase 1 study

(2011) JO Fleming et al.   Multiple Sclerosis Journal

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

(2011) S Cook et al.   Multiple Sclerosis Journal

Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation

(2011) Katja Herges et al.   PLoS One

Therapeutic Approaches to Multiple Sclerosis

(2010) Sven G. Meuth et al.   BIODRUGS

Therapeutic Approaches to Multiple Sclerosis

(2010) Jochen C. Ulzheimer et al.   BIODRUGS

Alpha2beta1 integrin is the major collagen-binding integrin expressed on human Th17 cells

(2010) Marc Boisvert et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein

(2010) Christopher T. Harp et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells

(2010) M. Yang et al.   JOURNAL OF IMMUNOLOGY

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial

(2010) Richard E Gonsette et al.   Multiple Sclerosis Journal

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients

(2010) Michael K. Hehir et al.   MUSCLE & NERVE

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)

(2010) Gina M. Remington et al.   Therapeutic Advances in Neurological Disorders

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

(2010) Elliot M. Frohman et al.   Therapeutic Advances in Neurological Disorders

Treatment of Neuromyelitis Optica With Mycophenolate Mofetil

(2009) Anu Jacob et al.   ARCHIVES OF NEUROLOGY

Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling

(2009) Dayong Wu et al.   FREE RADICAL BIOLOGY AND MEDICINE

Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs

(2009) I.M. Kapetanovic et al.   TOXICOLOGY

Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis

(2009) Lahar R Mehta et al.   Nature clinical practice. Neurology

Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

(2008) M. Krumbholz et al.   BRAIN

TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties

(2008) Fabienne Mackay et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity

(2008) R.E. Gonsette   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Complementary and alternative medicine for multiple sclerosis

(2008) S Schwarz et al.   Multiple Sclerosis Journal

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE